Induction systemic therapy followed by surgery for stages II–III non-small cell lung cancer: steady efforts

Ikuo Sekine, Yuka Aida, Hideo Suzuki


Lung cancer is the leading cause of mortality worldwide with 1.6 million deaths in 2012. The prognosis of lung cancer remains very poor (1). For most countries, the age-standardized 5-year survival rate ranges from 10% to 20% for most countries (2). Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung malignant tumors.